Alkermes (ALKS)
(Delayed Data from NSDQ)
$24.05 USD
+0.19 (0.80%)
Updated May 3, 2024 04:00 PM ET
After-Market: $24.08 +0.03 (0.12%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth A Momentum A VGM
Price, Consensus and EPS Surprise
ALKS 24.05 +0.19(0.80%)
Will ALKS be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ALKS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ALKS
Alkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates
Alkermes (ALKS) Reports Q1 Earnings: What Key Metrics Have to Say
ALKS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Alkermes (ALKS) Q1 Earnings and Revenues Miss Estimates
Deciphera Pharmaceuticals, Inc. (DCPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition?
Other News for ALKS
Alkermes Buy Rating Affirmed on Strong Commercial Performance and Promising Drug Pipeline
What's Driving Lantheus Holdings Inc's Surprising 27% Stock Rally?
Stifel Nicolaus Reaffirms Their Hold Rating on Alkermes (ALKS)
Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk
Russell 2000 Q1 2024 Earnings Preview: Sharp Downward Revisions Precede Earnings Season